Cargando…

Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer

Bemarituzumab (FPA144) is a first-in-class, humanized, afucosylated immunoglobulin G1 monoclonal antibody (mAb) directed against fibroblast growth factor receptor 2b (FGFR2b) with two mechanisms of action against FGFR2b-overexpressing tumors: inhibition of FGFR2b signaling and enhanced antibody-depe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiang, Hong, Chan, Abigael G., Ahene, Ago, Bellovin, David I., Deng, Rong, Hsu, Amy W., Jeffry, Ursula, Palencia, Servando, Powers, Janine, Zanghi, James, Collins, Helen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8565817/ https://www.ncbi.nlm.nih.gov/pubmed/34719330 http://dx.doi.org/10.1080/19420862.2021.1981202

Ejemplares similares

Covariate effects and population pharmacokinetic analysis of the anti-FGFR2b antibody bemarituzumab in patients from phase 1 to phase 2 trials
por: Xiang, Hong, et al.
Publicado: (2021)

Population pharmacokinetic analysis of phase 1 bemarituzumab data to support phase 2 gastroesophageal adenocarcinoma FIGHT trial
por: Xiang, Hong, et al.
Publicado: (2020)

Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma
por: Catenacci, Daniel V.T., et al.
Publicado: (2020)

Identification of novel immune regulators of tumor growth using RIPPS screening in vivo
por: Brennan, Tom, et al.
Publicado: (2015)

Identification of a novel immune checkpoint regulator and potential therapeutic antibody target in oncology
por: Sallee, Nathan, et al.
Publicado: (2015)

Enhanced FGFR signalling predisposes pancreatic cancer to the effect of a potent FGFR inhibitor in preclinical models
por: Zhang, H, et al.
Publicado: (2014)

Pharmacokinetics of Human Recombinant Anti-Botulinum Toxin Antibodies in Rats
por: Espinoza, Yero, et al.
Publicado: (2019)

Preclinical Evaluation of the FGFR-Family Inhibitor Futibatinib for Pediatric Rhabdomyosarcoma
por: Wu, Jerry T., et al.
Publicado: (2023)

Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models
por: Grünewald, Sylvia, et al.
Publicado: (2019)

Targeting FGFR4 Inhibits Hepatocellular Carcinoma in Preclinical Mouse Models
por: French, Dorothy M., et al.
Publicado: (2012)

Lysosomal Sequestration Impairs the Activity of the Preclinical FGFR Inhibitor PD173074
por: Englinger, Bernhard, et al.
Publicado: (2018)

Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation
por: Hall, Terence G., et al.
Publicado: (2016)

Preclinical Evaluation of the Pan-FGFR Inhibitor LY2874455 in FRS2-Amplified Liposarcoma
por: Hanes, Robert, et al.
Publicado: (2019)

Anti-Cyclic Citrullinated Peptide Antibody-Positive Meningoencephalitis in the Preclinical Period of Rheumatoid Arthritis
por: Shibahara, Tomoya, et al.
Publicado: (2016)

Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma
por: Tian, Meijie, et al.
Publicado: (2023)

Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models
por: Wu, Xiao Yu, et al.
Publicado: (2015)

Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models
por: Peng, Xia, et al.
Publicado: (2019)

FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro
por: Künstlinger, Helen, et al.
Publicado: (2015)

High Affinity Promotes Internalization of Engineered Antibodies Targeting FGFR1
por: Opaliński, Łukasz, et al.
Publicado: (2018)

Growth charts in FGFR2- and FGFR3-related faciocraniosynostoses
por: Ea, Caroline, et al.
Publicado: (2022)

Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
por: Facchinetti, Francesco, et al.
Publicado: (2023)

Enhanced network load balancing technique for efficient performance in software defined network
por: Osei Kofi, Evans, et al.
Publicado: (2023)

Novel mutation detection of fibroblast growth factor receptor 1 (FGFR1) gene, FGFR2IIIa, FGFR2IIIb, FGFR2IIIc, FGFR3, FGFR4 gene for craniosynostosis: A prospective study in Asian Indian patient
por: Barik, Mayadhar, et al.
Publicado: (2015)

Antibody-Mediated Activation of FGFR1 Induces FGF23 Production and Hypophosphatemia
por: Wu, Ai-Luen, et al.
Publicado: (2013)

Semi-Automated Cell Panning for Efficient Isolation of FGFR3-Targeting Antibody
por: Min, Byeongkwi, et al.
Publicado: (2021)

FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy
por: Quintanal-Villalonga, Álvaro, et al.
Publicado: (2020)

Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer
por: Weickhardt, Andrew J., et al.
Publicado: (2022)

Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment
por: Ruan, Ruiwen, et al.
Publicado: (2023)

Intrinsic FGFR2 and Ectopic FGFR1 Signaling in the Prostate and Prostate Cancer
por: Wang, Cong, et al.
Publicado: (2019)

The Evaluation of FGFR1, FGFR2 and FOXO1 in Orofacial Cleft Tissue
por: Goida, Jana, et al.
Publicado: (2022)

FGFR redundancy limits the efficacy of FGFR4-selective inhibitors in hepatocellular carcinoma
por: Tao, Zhanchao, et al.
Publicado: (2022)

Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors
por: Javle, Milind, et al.
Publicado: (2023)

Thinking security: stopping next year's hackers
por: Bellovin, Steven M
Publicado: (2016)

Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomas
por: Granberg, Kirsi J, et al.
Publicado: (2017)

Expression and clinical significance of FGFR1 and FGFR2 in laryngeal squamous cell carcinoma
por: Hu, Mengdie, et al.
Publicado: (2022)

Treatment approaches for FGFR-altered urothelial carcinoma: targeted therapies and immunotherapy
por: Benjamin, David J., et al.
Publicado: (2023)

Generation of Fgfr3 Conditional Knockout Mice
por: Su, Nan, et al.
Publicado: (2010)

9th USENIX Security Symposium
por: Bellovin, Steven, et al.
Publicado: (2000)

In situ analysis of FGFR2 mRNA and comparison with FGFR2 gene copy number by dual-color in situ hybridization in a large cohort of gastric cancer patients
por: Kuboki, Yasutoshi, et al.
Publicado: (2017)

Memory B cell and antibody responses to flavivirus infection and vaccination
por: Adam, Awadalkareem, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_33ffhgt9l3rppsdq4f7kf9gc4e